NCT01469169已完成3 期
A Multi-center, Non-randomized, Open Label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of BAY q 6256 (Iloprost) Inhalation in Patients With Pulmonary Arterial Hypertension (PAH)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 27
- 主要终点
- Number of participants with adverse events as a measure of safety and tolerability
研究概览
简要总结
This study is to investigate the efficacy, safety, and Pharmacokinetics (PK) of Inhaled Iloprost (Ventavis) therapy in Japanese pulmonary arterial hypertension (PAH) patients in Main Treatment Phase (12 weeks) and to investigate the safety, tolerability, and efficacy of longterm Inhaled Iloprost (Ventavis) therapy in Japanese PAH patients in Extension Phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects aged 18 to 75 years
- •Symptomatic Pulmonary Artery Hypertension (PAH) classified (Dana Point Classification 1)
- •New York Heart Association (NYHA)/World Health Organization (WHO) functional class III or IV
- •PAPmean at rest > 25 mm Hg, Pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure </= 15 mm Hg and Pulmonary Vascular resistance (PVR) >/= 240 dyn.sec.cm-5 (>/= 400 dyn.sec.cm-5 for patients treated with both endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5i) ) as measured by Right Heart Catheter test
- •Women of childbearing potential and men must agree to use adequate contraception when sexually active
排除标准
- •Baseline 6-minute walk distance of less than 100 meters or more than 500 meters
- •Subjects with critical severe PAH
- •Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio < 60% and/or Total Lung Capacity (TLC) < 70% predicted (especially at interstitial lung disease, TLC < 60% predicted)
- •Clinically relevant obstructive lung disease (e.g. asthma or chronic obstructive pulmonary disease )
- •More than mild patchy interstitial lung disease on High Resolution Computerized Tomography (HRCT)
- •History of left-sided heart disease
- •Uncontrolled systemic hypertension as evidenced by systolic blood pressure >/= 160 mm Hg or diastolic blood pressure >/= 100 mm Hg on repeated measurement
- •Systemic hypotension with systolic blood pressure < 85 mm Hg
研究组 & 干预措施
Arm 1
Experimental
干预措施: Iloprost (Ventavis inhaled, BAYQ6256) (Drug)
结局指标
主要结局
Number of participants with adverse events as a measure of safety and tolerability
时间窗: Over 52 weeks
Change in Pulmonary vascular resistance (PVR) from screening (baseline) to week 12 (after inhalation)
时间窗: At baseline and 12 weeks
Area under the plasma concentration vs time curve from start of inhalation to infinity after single inhalation (AUC)
时间窗: At baseline, 12 weeks, 52 weeks and over 52 weeks
Maximum drug concentration in plasma after start of inhalation (Cmax)
时间窗: Up to 12 weeks
次要结局
- Change in Mean arterial pressure (MAP)(At baseline and 12 weeks)
- Change of systolic pulmonary artery pressure from baseline to week 12(At baseline and 12 weeks)
- Change in Pulmonary capillary wedge pressure (PCWP)(At baseline and 12 weeks)
- Change Mixed venous oxygen saturation (SVO2)(At baseline and 12 weeks)
- Change in 6-minute walking test (6MWT)(At baseline, 12 weeks and 52 weeks)
- Quality of life assessed by EQ-5D and Living with Pulmonary Hypertension (LPH) questionnaires(At baseline, 12 weeks and 52 weeks)
- Mortality during the study(At baseline, 12 weeks, 52 weeks and over 52 weeks)
- Half-life associated with the terminal slope (t1/2)(Up to 12 weeks)
- Change of Pulmonary vascular resistance index (PVRI) from baseline to week 12(At baseline and 12 weeks)
- Change of mean of pulmonary artery pressure from baseline to week 12(At baseline and 12 weeks)
- Change of diastolic pulmonary artery pressure from baseline to week 12(At baseline and 12 weeks)
- Change in Mean right atrial pressure (RAPm)(At baseline and 12 weeks)
- Change in Cardiac output (CO)(At baseline and 12 weeks)
- Change in Systemic vascular resistance (SVR)(At baseline and 12 weeks)
- Change in Cardiac index(At baseline and 12 weeks)
- Change in Borg CR 10 Score(At baseline, 12 weeks and 52 weeks)
- Change in N-terminal pro-B-type natriuretic peptide (NT-ProBNP)(At baseline, 12 weeks and 52 weeks)
- AUC divided by dose per kg body weight (AUCnorm)(Up to 12 weeks)
- Need for transplantation during the study(At baseline, 12 weeks, 52 weeks and over 52 weeks)
- Change in Systemic vascular resistance index (SVRI)(At baseline and 12 weeks)
- AUC from time start of inhalation to the last data point AUC(0-tlast)(Up to 12 weeks)
- Change in New York Heart Association/ World Health Organization (NYHA/WHO) class(At baseline, 12 weeks, 52 weeks and over 52 weeks)
- Time to clinical worsening during the study(At baseline, 12 weeks, 52 weeks and over 52 weeks)
- AUC divided by dose (μg) (AUC/D)(Up to 12 weeks)
- Maximum drug concentration in plasma after start of inhalation divided by dose (μg) per kg body weight (Cmax,norm)(Up to 12 weeks)
- Maximum drug concentration in plasma after start of inhalation divided by dose (μg) (Cmax/D)(Up to 12 weeks)
- Time to reach maximum drug concentration in plasma after start of inhalation (tmax )(Up to 12 weeks)
研究者
相似试验
终止
4 期
Outpatient Vasodilator Assessment Using Iloprost in Pulmonary HypertensionPulmonary HypertensionNCT03044314Duke University27
已完成
2 期
Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart DiseasePulmonary HypertensionNCT01320878Shanghai Jiao Tong University School of Medicine64
进行中（未招募）
1 期
Acute effect of iloprost inhalation on pulmonary hypertension developed during exercise in Post-COVID-19 patientsEUCTR2022-003725-22-DEJustus-Liebig-University Gießen120
撤回
2 期
Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionNCT00453414Actelion
已完成
2 期
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary FibrosisPulmonary HypertensionPulmonary FibrosisNCT00109681Actelion50